You can buy or sell Aptinyx and other stocks, options, ETFs, and crypto commission-free!
Aptinyx Inc. Common Stock, also called Aptinyx, is a clinical stage biopharmaceutical company. Read More It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
52 Week High
52 Week Low
Associated PressMar 22
Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. EVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today anno...
Seeking AlphaMar 21
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2018 Results - Earnings Call Transcript
Aptinyx Inc. (NASDAQ:APTX) Q4 2018 Results Conference Call March 21, 2019 8:00 AM ET Company Participants Nick Smith - Senior Director, Corporate Development Norbert Riedel - President and CEO Ashish Khanna - CFO and Chief Business Officer Andy Kidd - COO Conference Call Participants Gerard Smith - SVB Leerink Gary Nachman - BMO Capital Markets Sadia Rahman - Charles Duncan Jessica Fye - J.P. Morgan Operator Good morning and welcome to the Aptinyx Fourth Quarter and Year-End 2018 Financial Resul...
Seeking AlphaMar 21
Aptinyx reports Q4 results
Aptinyx (APTX) Q4 results: Revenues: $1M (-16.7%). Net Loss: ($14.1M) (-95.8%); Loss Per Share: ($0.42) (+69.1%); Quick Assets: $150.6M (+63.5%). The Company initiated Phase 2a study of NYX-783 in patients with PTSD, data expected in 1H 2020. Also, Aptinyx is nearing completion of Phase 1 study of NYX-458 in healthy volunteers with data expected in 1H 2019. Previously: Aptinyx beats by $0.08, misses on revenue (March 21)...
-$0.50 per share
-$0.42 per share